Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas

Melanoma Research

Volumn 5, Issue 4, 1995, Pages 243-250

  Vidal, M J ^a   Loganzo, F ^a   de Oliveira, A R ^a   Hayward, N K ^b   Albino, A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CELL LINE; COMPARATIVE STUDY; CYCLINS; DNA, NEOPLASM; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMAN; LYMPHOCYTES; MELANOCYTES; MELANOMA; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN P53; REFERENCE VALUES; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T;

EID: 0028997764     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/00008390-199508000-00006     Document Type: Article

References (52)

1. Sober AJ, Lew RA, Koh HK, et al. Epidemiology of cutaneous melanoma. An update, Dermatol Clin 1991; 9: 617-629.
2. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325 171-182.
3. Halaban R, Moellmann G. Proliferation and malignant transformation of melanocytes. Crit Rev Oncol 1991; 2: 247-258.
4. Albino AP, Fountain JW. The molecular genetics of malignant melanoma. In: Nathanson L, ed. Cancer Treatment and Research Basic and Clinical Aspects of Malignant Melanoma. Boston: Martinus Nijhoff Publishers, 1993; 201-255.
5. Vogelstem B, Kinzler KW. The multistep nature of cancer. Trends Cenet 1993; 9: 138-141.
6. Sherr JC. Mammalian Gl cyclins. Cell 1993; 73: 1059-1065.
7. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
8. Harper JW, Adami GR, Wei N, et al The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases Cell 1993; 75 805-816.
9. Xiong Y, Hannon GJ, Zhang H, el al. p21 is universal inhibitor of cyclin kinases Nature 1993; 366: 701-704.
10. El-Deiry WS, Harper JW, O'Connor PM, et al WAF1/CIP1 is induced in p53-mediated Gl arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
11. Stretch JR, Gatter KC, Ralfkiaer E, et al. Expression of mutant p53 in melanoma Cancer Res 1991; 51; 5976-5979.
12. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-1703.
13. Albino AP, Vidal M, McNutt NS, et al. Mutation and expression of the p53 gene in human malignant melanoma Melanoma Res 1994; 4: 35-45.
14. Walker GJ, Nancarrow DJ, Walters MK, et al. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer 1994; 59: 771-775.
15. Albino AP, Lloyd KO, Houghton AN, et al. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens J Exp Med 1981; 154: 1764-1778.
16. Eisinger M, Marko O. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci USA 1982; 79: 2018-2022.
17. Nancarrow D, Palmer J, Walters M, et al Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome ami lp in 7 Australian pedigrees. Genomics 1992; 12: 18-25.
18. Nancarrow D, Walker G, Weber J, et al Linkage mapping of melanoma (MLM) using 172 microsatellite markers Genomics 1992; 14: 939-947.
19. Nancarrow D, Mann G, Holland E, et al Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993; 53 936-942.
20. Sambrook J, Fritsch EF, Maniatis T, Molecular Cloning: A Laboratory Manual Cold Spring HarbonCold Spring Harbor Laboratory Press, 1989.
21. Miller SA, Dykes DO, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215-1217.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
23. Chedid M, Michieli P, Lengel C, et al. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in i highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 1994; 9: 3021-3024.
24. Orita M, Iwahana H, Kanazawa H, et al Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci I'SA 1989; 86: 2766-2770.
25. Orita M, Suzuki Y, Sekiya T, et al Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction Genomics 1989; 5: 874-879.
26. Saiki RK, Gelfand DH, Stoffel S, et al Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase Science 1988; 239: 487-491.
27. Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of beta-glohin genomic sequences and restriction site-analysis lor diagnosis ot sickle cell anemia Science 1985; 230: 1350-1354.
28. Albino AP, Nanus DM, Mentle IR, et al Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype Oncogene 1989; 4: 1363-1374.
29. Murray V. Improved double-stranded DNA sequencing using the linear polymerase chain reaction Nucleic Acids Res 1989; 17: 8889.
30. Dicker AP, Volkenandt M, Albino AP. Mutational analysis of human NRAS genes in malignant melanoma: rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reaction. Genes Chrom Cancer 1990; 1: 257-269.
31. Loganzojr F, Nabeya Y, Maslak P, et al Stabilization of p53 protein is a critical response to UV radiation in human melanocytes: implications for melanoma development Mol Cell Differ 1994; 2: 23-43.
32. Hunter T. Braking the cycle Cell 1993; 75: 839-841.
33. Greene MH and Fraumeni Jr, JF. The hereditary variant of malignant melanoma. In. Clark Jr, W.H.. Goldman LI, Mastrangelo MJ, eds. Human Malignant Melanoma, New York: Grune & Stratton, 1979; 139-166.
34. Cannon Albright L, Goldgar D, Meyer L, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258: 1148-1152.
35. Goldstein A, Dracopoli N, Engelstein M, et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity Am J Hum Genet 1994; 54: 489-496.
36. Goldstein A, Dracopoli N, Ho E, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome lp, and evidence for genetic heterogeneity Am J Hum Genet 1993; 52: 537-550.
37. Lin D, Shields MT, Ullrich SJ, et al. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late Gl phase. Proc Natl Acad Sci USA 1992; 89: 9210-9214.
38. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer lies 1991; 51: 6304-6311.
39. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc Natl Acad Sci USA 1992; 89: 7491-7495.
40. Volkenandt M, Schlegel U, Nanus DM, et al. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991; 4: 35-40.
41. Cristofolini M, Boi S, Girlando S, et al. p53 protein expression in nevi and melanomas Arch Dermatol 1993; 129. 739-743.
42. Akslen LA, Morkve O Expression of p53 protein in cutaneous melanoma Int J Cancer 1992; 52. 13-16.
43. McNutt NS, Saenz Santamaria C, Volkenandt M, et al. Abnormalities of p53 protein expression in cutaneous disorders Arch Dermatol 1994; 130: 225-232.
44. Michieh P, Chedid M, Lin D. et al Induction of WAF1/CIP1 by p53-independent pathway Cancer Res 1994, 54 3391-3395.
45. Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma In Franks LM, ed. Cancer Surveys: Advances and Prospects in Clinical. Epidemiological and Laboratory Oncology London Oxford University Press, 1990: 645-671.
46. Kamb A, Gruis NA, Weaver-Feldhaus J, et al A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
47. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin dependent kinase-4 inhibitor gene in multiple human cancers Nature 1994; 368; 753-756.
48. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 1993; 366: 704-707.
49. Isshiki K, Seng BA, Elder DE, et al. Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene 1994; 9: 1649-1653.
50. Fountain JW, Haluska FG, Walker GJ, et al Homozygous deletions of 9p21 in sporadic melanoma in vivo target a broad region, including the CDKN2 gene Cancer Res 1995 (submitted)
51. Hussussian CJ, Struewing JP, Goldstein AM. et al. Germline p16 mutations in familial melanoma Nature Genet 1994; 8: 15-21.
52. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994; 8: 22-26.